Therapeutic Antibody Development Services for Cardiovascular Diseases

In recent years, with the rapid development and wide application of antibodies in medical practice, it has become possible to use therapeutic antibodies as an applied strategy for the treatment of cardiovascular diseases. As a company with extensive experience in therapeutic antibody development, Ace Therapeutics is able to provide integrated services to help our clients accelerate the therapeutic antibody development process for cardiovascular diseases.

Inflammation-based Antibody Therapeutics for Cardiovascular Diseases

It is generally believed that inflammation plays a significant role in the pathogenesis of cardiovascular diseases. Therefore, the development of therapeutic antibodies against relevant pro-inflammatory cytokines is one of the current directions in targeted therapeutic strategies for cardiovascular diseases.

• Anti-TNF-α
  The pro-inflammatory cytokine TNF-α has been highlighted as an effective therapeutic target for cardiovascular disease. It has shown that the anti-TNF-α antibody therapy can significantly reduce cardiovascular risk.
• Anti-IL-1β
  It has been reported that IL-1 is a key factor in the atherosclerotic process. Among the marketed drugs, Canakinumab is a human monoclonal antibody against IL-1β that is already in clinical use.
• Anti-IL-6
  IL-6 is induced by pro-inflammatory cytokines such as IL-1 and TNF cytokines and acts as a central hub for atherosclerotic inflammatory signaling. Tocilizumab is a humanized monoclonal antibody against the IL-6 receptor that interferes with the binding between IL-6 and IL-6 receptors.

Fig. 1 Antibodies targeting cytokines and cytokines acting on atherosclerotic plaque. (Ji E, Lee S, 2021)

With a leading antibody development platform, Ace Therapeutics offers comprehensive services for the development of therapeutic antibodies for cardiovascular diseases, covering the antibody development process from target identification to preclinical studies.

Target Identification and Validation for Therapeutic Antibodies

We first identify key proteins, receptors and pathways associated with cardiovascular diseases as targets for therapeutic antibody development. Common antibody targets include inflammatory cytokines, adhesion molecules, growth factors and extracellular matrix proteins.

Therapeutic Antibody Production

• Hybridoma Technique
  We can immunize mice with a target antigen to generate a specific immune response. B cells from the immunized mice are then fused with myeloma cells to generate hybridomas that produce monoclonal antibodies.
• Phage Display Libraries
  We can screen phage display libraries to identify antibodies that bind to the target antigen and optimize the lead antibody through iterative screening.

Therapeutic Antibody Optimization

The binding targets of therapeutic antibodies for cardiovascular diseases are usually inflammatory cytokines, adhesion molecules, and growth factors in the blood. We can optimize the antibody sequence and design the Fc region of the antibody to improve the stability of the antibody in the blood environment and improve its pharmacokinetic profile.

In Vitro Validation of Therapeutic Antibodies

• Validation of Antibody Affinity
  We can measure real-time binding interactions between antibodies and their target antigens by surface plasmon resonance (SPR) and enzyme-linked immunosorbent assay (ELISA), providing data on affinity and kinetics for therapeutic antibody in cardiovascular diseases.
• Validation of Antibody Function
  We can perform functional assays related to the intended use of the antibody to ensure the functional specificity and reliability of therapeutic antibodies for the treatment of cardiovascular diseases.
• Validation of Antibody Stability
  We perform a variety of antibody stability testing, including thermal, chemical and long-term storage stability, to ensure that the therapeutic antibodies for cardiovascular disease maintain their functionality over their intended shelf life.

Preclinical Evaluation of Therapeutic Antibodies

We can evaluate the efficacy as well as the safety of antibodies in animal models of cardiovascular disease, and conduct systematic preclinical efficacy and toxicology studies, including immunogenicity and off-target effects.

Ace Therapeutics is a contract research organization engaged in cardiovascular disease drug discovery research. We are able to provide therapeutic antibody discovery and development services based on our clients' research needs. If you are interested in our services, please do not hesitate to contact us.

1. Ji, E.; Lee, S. Antibody-based therapeutics for atherosclerosis and cardiovascular diseases. Int J Mol Sci. 2021, 22(11):5770.